Enveda nabs $311m to progress nature-derived drug pipeline

The cash will primarily fund Enveda’s continued development of three clinical-stage assets for inflammatory and metabolic disorders.

Summary from Pharmaceutical Technology.

Coverage 1 article · 1 outlet

1. Pharmaceutical Technology 15h ago
   Enveda nabs $311m to progress nature-derived drug pipeline ↗